JPWO2024242065A1 - - Google Patents
Info
- Publication number
- JPWO2024242065A1 JPWO2024242065A1 JP2025515487A JP2025515487A JPWO2024242065A1 JP WO2024242065 A1 JPWO2024242065 A1 JP WO2024242065A1 JP 2025515487 A JP2025515487 A JP 2025515487A JP 2025515487 A JP2025515487 A JP 2025515487A JP WO2024242065 A1 JPWO2024242065 A1 JP WO2024242065A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023082728 | 2023-05-19 | ||
| JP2023082728 | 2023-05-19 | ||
| PCT/JP2024/018410 WO2024242065A1 (ja) | 2023-05-19 | 2024-05-17 | 核酸送達用構造体の造血器腫瘍の治療への使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2024242065A1 true JPWO2024242065A1 (https=) | 2024-11-28 |
| JPWO2024242065A5 JPWO2024242065A5 (https=) | 2025-06-03 |
| JP7725042B2 JP7725042B2 (ja) | 2025-08-19 |
Family
ID=93589879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025515487A Active JP7725042B2 (ja) | 2023-05-19 | 2024-05-17 | 造血器腫瘍治療用組成物、造血器腫瘍治療用医薬、及び造血器腫瘍における癌化細胞の増殖抑制用組成物 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4714453A1 (https=) |
| JP (1) | JP7725042B2 (https=) |
| CN (1) | CN121175056A (https=) |
| AU (1) | AU2024276929A1 (https=) |
| WO (1) | WO2024242065A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022230990A1 (ja) * | 2021-04-28 | 2022-11-03 | 国立研究開発法人科学技術振興機構 | 人工核酸及びそれを用いた核酸の送達方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10487103B2 (en) | 2015-03-24 | 2019-11-26 | Gifu University | Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them |
| WO2017179660A1 (ja) | 2016-04-14 | 2017-10-19 | 国立大学法人岐阜大学 | マイクロｒｎａ－１４３誘導体 |
-
2024
- 2024-05-17 AU AU2024276929A patent/AU2024276929A1/en active Pending
- 2024-05-17 EP EP24811072.8A patent/EP4714453A1/en active Pending
- 2024-05-17 CN CN202480032385.1A patent/CN121175056A/zh active Pending
- 2024-05-17 JP JP2025515487A patent/JP7725042B2/ja active Active
- 2024-05-17 WO PCT/JP2024/018410 patent/WO2024242065A1/ja not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022230990A1 (ja) * | 2021-04-28 | 2022-11-03 | 国立研究開発法人科学技術振興機構 | 人工核酸及びそれを用いた核酸の送達方法 |
Non-Patent Citations (1)
| Title |
|---|
| 平島 一輝: "miR-143-ナノ脂質抱合粒子を用いたKRAS変異多発性骨髄腫治療法の開発", 科学研究費助成事業 研究成果報告書, vol. 課題番号：２０Ｋ１６２１６, JPN6024026980, 20 June 2022 (2022-06-20), ISSN: 0005593127 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7725042B2 (ja) | 2025-08-19 |
| EP4714453A1 (en) | 2026-03-25 |
| AU2024276929A1 (en) | 2025-12-18 |
| WO2024242065A1 (ja) | 2024-11-28 |
| CN121175056A (zh) | 2025-12-19 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250312 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250312 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20250312 |
|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20250325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250327 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250711 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250729 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250729 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7725042 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |